Filing Analysis
Adicet Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected three Class II directors, approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on June 17, 2026.
- Jeffrey Chodakewitz, Steve Dubin, and Michael Grissinger were elected as Class II directors for three-year terms ending in 2029.
- Executive compensation for named executive officers was approved on a non-binding advisory basis (4,611,540 votes for vs 745,537 against).
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Adicet Bio, Inc. announced its financial results for the fiscal quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the first quarter of 2026.
- The report was filed on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Adicet Bio entered into an exchange agreement with RA Capital to swap 250,000 shares of common stock for a pre-funded warrant for an equivalent number of shares. This transaction allows the institutional investor to manage beneficial ownership thresholds while maintaining its economic exposure to the company.
📋 Key Facts
- On April 27, 2026, the Company exchanged 250,000 shares of common stock for a pre-funded warrant with RA Capital.
- The pre-funded warrant allows for the purchase of 250,000 shares at a nominal exercise price of $0.0001 per share.
- The warrant includes a beneficial ownership blocker of 9.99%, which can be increased to 19.99% upon 61 days' notice.
- The transaction was conducted as an unregistered exchange under Section 3(a)(9) of the Securities Act of 1933.
- The exchange is non-dilutive relative to the total shares and equivalents already held by the investor.
Adicet Bio, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Reported financial results for the quarter and year ended December 31, 2025
- Filing date: March 12, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release